View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 6, 2011

Talactoferrin Found Effective for Sepsis

Agennix has announced positive results from a Phase II trial to evaluate talactoferrin, an oral immunotherapy, as a treatment for severe sepsis. The randomised study evaluated 190 patients and showed that talactoferrin reduced mortality and was well-tolerated in patients with severe sep

By cms admin

Agennix has announced positive results from a Phase II trial to evaluate talactoferrin, an oral immunotherapy, as a treatment for severe sepsis.

The randomised study evaluated 190 patients and showed that talactoferrin reduced mortality and was well-tolerated in patients with severe sepsis.

The Phase II trial was primarily funded by a grant from the US National Institutes of Health.

The findings from the study were presented at the 14th World Conference on Lung Cancer of the International Association for the Study of Lung Cancer in Amsterdam, the Netherlands.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology